4-Ethoxy-nicotinsaeure | 53623-62-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-Ethoxy-nicotinsaeure
• 英文别名: 4-ethoxy-nicotinic acid；4-Ethoxynicotinic acid；4-ethoxypyridine-3-carboxylic acid
• CAS: 53623-62-4
• 化学式: C₈H₉NO₃
• 分子量: 167.164
• InChiKey: AJROXNAIZAXDDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

文献信息

• STABLE CANNABINOID COMPOSITIONS
  申请人：cbdMD, Inc.

  公开号：US20210401746A1

  公开（公告）日：2021-12-30

  The present application discloses powder and aqueous formulations. These include but are not limited to water dispersible cannabinoid formulations, especially those comprising cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN) as well as other cannabinoids. Generally, these embodiments do not include major amounts of Tetrahydrocannabinol (THC), but certain embodiments are envisioned that do contain measurable concentrations of THC. Embodiments may include one or more emulsifiers selected from the group consisting of Tween (polysorbate) 20, Tween 60, Tween 80, Span 20, Span 60, Span 80, Poloxamer 188, Vit E-TPGS (TPGS), TPGS-1000, TPGS-750-M, Solutol HS 15, PEG-40 hydrogenated castor oil, PEG-35 Castor oil, PEG-8-glyceryl capylate/caprate, PEG-32-glyceryl laurate, PEG-32-glyceryl palmitostearate, Polysorbate 85, polyglyceryl-6-dioleate, sorbitan monooleate, Capmul MCM, Maisine 35-1, glyceryl monooleate, glyceryl monolinoleate, PEG-6-glyceryl oleate, PEG-6-glyceryl linoleate, oleic acid, linoleic acid, propylene glycol monocaprylate, propylene glycol monolaurate, polyglyceryl-3 dioleate, polyglyceryl-3 diisostearate and lecithin.

  本申请公开了粉末和水性配方。这些配方包括但不限于水分散型大麻素配方，特别是那些包含大麻二酚（CBD）、大麻二醇（CBG）和大麻酚（CBN）以及其他大麻素的配方。一般来说，这些实施例不包括大量的四氢大麻酚（THC），但也设想了一些包含可测量浓度的THC的实施例。实施例可能包括从Tween（聚山梨醇酯）20、Tween 60、Tween 80、Span 20、Span 60、Span 80、Poloxamer 188、维生素E-TPGS（TPGS）、TPGS-1000、TPGS-750-M、Solutol HS 15、PEG-40氢化蓖麻油、PEG-35蓖麻油、PEG-8-辛酸/癸酸甘油酯、PEG-32-月桂酸甘油酯、PEG-32-棕榈酸甘油酯、Polysorbate 85、聚甘油-6-二油酸酯、山梨醇单油酸酯、Capmul MCM、Maisine 35-1、甘油单油酸酯、甘油单亚油酸酯、PEG-6-甘油油酸酯、PEG-6-甘油亚油酸酯、油酸、亚油酸、丙二醇单癸酸酯、丙二醇单月桂酸酯、聚甘油-3-二油酸酯、聚甘油-3-异硬脂酸酯和卵磷脂中选择的一种或多种乳化剂。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：AMURA THERAPEUTICS LTD

  公开号：WO2009112839A1

  公开（公告）日：2009-09-17

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: R3 is selected from cyclopentyl and cyclohexyl; R9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high dual efficacies for human cathepsin S and K and are useful for the treatment of rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, cardiovascular diseases which exhibit significant damage and remodeling of extracellular matrix (ECM) and chronic pain.

  本发明的第一个方面涉及公式(I)的化合物，或其药学上可接受的盐、水合物、复合物或前药，其中：R3选自环戊基和环己基；R9是取代的5或6成员芳基或杂芳基或6,5-或6,6-融合的双芳基或双杂芳基。公式(I)的化合物表现出对人类卡特普汀S和K的惊人双重功效，并可用于治疗类风湿性关节炎、骨关节炎、慢性阻塞性肺病（COPD）、动脉粥样硬化、心血管疾病，这些疾病表现出显着的细胞外基质（ECM）的损伤和重塑以及慢性疼痛。
• Pharmaceutical compositions of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20010053778A1

  公开（公告）日：2001-12-20

  Pharmaceutical compositions comprise a glycogen phosphorylase inhibitor and at least one concentration-enhancing polymer. The composition may be a simple physical mixture of glycogen phosphorylase inhibitor and concentration-enhancing polymer or a dispersion of glycogen phosphorylase inhibitor and polymer.

  药物组合物包括一种糖原磷酸化酶抑制剂和至少一种浓度增强聚合物。该组合物可以是糖原磷酸化酶抑制剂和浓度增强聚合物的简单物理混合物，也可以是糖原磷酸化酶抑制剂和聚合物的分散体。
• Compositions comprising an HIV protease inhibitor
  申请人：Smith Wendell Scott

  公开号：US20050129772A1

  公开（公告）日：2005-06-16

  The present invention relates to pharmaceutical compositions comprising amorphous (4R)—N-allyl-3-(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, their methods of preparation, their use in inhibiting the HIV protease enzyme, and their use in treating HIV-infected mammals, such as humans.

  本发明涉及制药组合物，包括非晶态(4R)-N-烯丙基-3-(2S,3S)-2-羟基-3-[(3-羟基-2-甲基苯甲酰)氨基]-4-苯基丁酰}-5,5-二甲基-1,3-噻唑烷-4-羧酰胺或其药学上可接受的盐或溶剂，它们的制备方法，它们在抑制HIV蛋白酶酶中的使用以及它们在治疗HIV感染的哺乳动物，例如人类中的使用。
• Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
  申请人：Pfizer Inc

  公开号：US20040132771A1

  公开（公告）日：2004-07-08

  A composition comprises (1) a solid amorphous adsorbate comprising a cholesteryl ester transfer protein (CETP) inhibitor and a substrate; and (2) an HMG-CoA reductase inhibitor. The solid amorphous adsorbate provides concentration enhancement of the CETP inhibitor relative to a control composition consisting essentially of the unadsorbed CETP inhibitor alone, resulting in improved bioavailability.

  这篇文章包括(1)一个固态无定形吸附剂，其中包含一个胆固醇酯转移蛋白(CETP)抑制剂和一个底物;和(2)一个HMG-CoA还原酶抑制剂。固态无定形吸附剂相对于仅由未吸附的CETP抑制剂组成的对照组成分提供了CETP抑制剂的浓度增强，从而提高了生物利用度。